Daniel Dornbusch has over 25 years of experience building pharmaceutical and biotechnology companies and currently serves as the CEO of Excision BioTherapeutics, a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases including HIV, Hepatitis and Herpes. He has held management roles in large pharmaceutical, small biotechnology, and diagnostics companies spanning business development, mergers and acquisitions, marketing, sales, commercial strategy, and product development. He was the founding CEO of Acteris, Inc, serves on the board of Arrow Pharmaceuticals, and held senior roles at Nodality. Daniel worked in roles of increasing responsibility at Novartis in business development and international commercial leading territories in the US and Latin America. Daniel led commercial teams at Genentech and started his career at the Genzyme Corporation, serving in various roles including business development, product management, and corporate development. Daniel received his B.A. in Biology and English from Cornell University, M.S. from Tufts University School of Medicine and Emerson College, and M.B.A. from the Harvard Business School.